Cardiovascular Risk Assessment in Primary Osteoporosis by Armstrong, DJ et al.
©  The Ulster Medical Society, 2006.





2.00pm     Welcome   Chairman:  Dr David Higginson
2.05pm    Papers
3.20pm    Afternoon Tea
3.50pm     Papers
4.05pm     Two case presentations from Erne Hospital 
4.20pm  Invited Abstract:  ”The patient with neurological 
symptoms - pathological or functional?” Dr SA 
Hawkins, Consultant Neurologist and Reader in 
Medicine,  Royal Victoria  Hospital  and  Queens 
University Belfast.
5.00pm     Close
PRESENTED ABSTRACTS
An Epidemiological Study of Multiple Sclerosis in the North-
East Region of Northern Ireland.
OM Gray, GV McDonnell, SA Hawkins.
Royal Victoria Hospital, Grosvenor Road, Belfast, N. Ireland. 
BT12 6BA.
Objective:  To estimate the prevalence of multiple sclerosis 
(MS).
Background:  NI has been recognised to be an area of high 
risk for MS.  The original study of Allison and Millar in 1951 
found a prevalence of 41 per 100,000.  Subsequent studies 
in 1951, 1961, 1986 and 1996 suggested prevalence rising 
serially - 57, 104 and 168.2 per 100,000.
Methods:  We surveyed the North-East of NI (population 
160,446, area 2,030 km2).  Sources of cases included the 
Northern  Ireland  Neurology  Service  records,  general 
practitioners, hospital discharge coding, MS charities, MS 
specialist nurses and respite facilities.  Cases complied with 
the Poser criteria or the McDonald criteria.
Results:  From a provisional list of 469 cases, 370 (123 
males, 247 females) were identified with definite MS.  The 
prevalence was 230.6 per 100,000 (95% CIs 207.0-255.4) with 





than males (157.0 / 100,000).  Mean age on prevalence day 
was 50.3 years (SD 14.0).  Mean age at onset was 32.6 years 
(SD 10.5). Mean delay between onset and diagnosis was 4.6 
years.
Conclusions:  NI continues to have a rising prevalence of 
MS.  This may in part be due to improved case ascertainment, 
improved diagnostic techniques and improved awareness of 
MS.
Cardiovascular Risk Assessment in Primary Osteoporosis
DJ Armstrong, ASH Lee, M McQuilkin, MB Finch*
Department  of  Rheumatology,  Musgrave  Park  Hospital, 
Greenpark Healthcare Trust, Belfast, *Department of Life and 
Health Sciences, University of Ulster, Jordanstown
Background:  There  is  increased  awareness  of  the  need 
for cardiovascular (CVS) risk monitoring in the Northern 
Ireland  population  in  general,  and  amongst  rheumatoid 
arthritis and SLE patients in particular, who have a higher 
incidence of cardiovascular disease. No clear guidelines exist 
for cardiovascular risk monitoring in osteoporosis, and the 
prevalence and associations of known CVS risk factors are 
largely unquantified.
Aim: To estimate current levels of CVS risk monitoring in 
primary osteoporosis patients, and then perform a CVS risk 
assessment,  together  with  measures  of  bone  health,  bone 
mineral density (BMD) and fracture risk.
Methods:  History  and  examination  of  80  patients  at  a 
dedicated multidisciplinary osteoporosis clinic at Musgrave 
Park Hospital, together with BMD measurement and blood 
sampling for lipids, glucose and urate measurement.
Results:  80  primary  osteoporosis  patients  (10  male,  70 
female, median age 67.0 years (95%CI 65.0-70.0), median 
onset 63.0 years, (95%CI 60.0-65.0)) were assessed. 57 (71%) 
recalled a blood pressure check in the previous year, but just 
35 (43.8%) had received a lipid check, and only 26 (32.5%) 
a test for diabetes. 8 patients had systolic blood pressure 
(BP) >160mmHg, and 7 diastolic BP >90mmHg (definitely 
hypertensive).  31  (38.8%)  had  systolic  BP  >140mmHg 
and  41  (51.1%)  had  diastolic  BP>80mmHg  )  (borderline 
hypertension).  14  (17.5%)  of  patients  had  already  been 
diagnosed with angina, myocardial infarction or stroke.
There was a striking and previously unreported relationship 
between  diastolic  BP  and  having  suffered  a  low  trauma 
fracture.  Patients  without  fracture  (n=38)  had  a  median 
diastolic BP of  70.0 (95%CI 65.9-76.1 ) compared with 85.0 
(95%CI 80.0-88.0) in patients who had sustained at least one 
fracture (n=42) (p<0.001). There was no relationship with 
diastolic BP and steroid or bisphosphonate use. 
There was also a previously unreported correlation between 
lower HDL levels and BMD at the hip (r=-0.28, p=0.02). Hip 
BMD in patients with HDL<1.5 v HDL>1.5 0.765 (95%CI 
0.731-0.823) v 0.726 (95%CI 0.624-0.785), p=0.05. There 
was no relation with statin use. Overall, 38 (47.5%) patients 
had cholesterol levels >5.2 mmol/l, and just 14 patients were 
taking lipid lowering therapy.
Conclusion:  There  is  a  substantial  unmet  need  for 
cardiovascular  risk  assessment  in  primary  osteoporosis, 
in  which  cardiovascular  disease  is  common.  There  are 
potentially interesting links between hypertension and lipid 
abnormalities and some aspects of bone health, which merit 
further investigation. All these patients will have regular CVS 
monitoring at our clinic.
Effect  of  a  new  chest  pain  clinic  on  cardiology  referral 
patterns.
JDS  Higginson,  M  Dooley,  A  Tait,  SR  McMechan,  DJ 
Cochrane 
Cardiology Department, Ulster Hospital, Belfast.
A new chest pain clinic (CPC) saw 106 patients in the first 
two months (February and March 2006). A final report with 
diagnosis, recommended treatment or further investigation 
was faxed within 24 hours.
Most referrals were from GPs (66%), with 14% from the 
Emergency  Department  (ED)  or  Clinical  Decision  Unit. 
Cardiologists referred 20% from routine referral letters to 
cardiology out-patients (OP).
The diagnosis was non-cardiac chest pain in 65%, stable/
possible angina 30%, unstable angina 4%. No patients had 
myocardial infarction.
The  final  outcomes  were  referral  back  to  GP  in  62%, 
cardiology OP referral 31%, medical OP referral 3% and 4% 
patients were admitted.
Further cardiac investigations, mostly coronary angiography, 
were planned in 30%    patients.  If the CPC had not been 
available, the referring doctor would have sent 32% patients to 
cardiology OP, 27% to another chest pain clinic, 23% for open 
access investigation, 13% to the ED and 4% for admission.
We concluded that the CPC had resulted in a small reduction 
in GP referrals to the ED. The reduction in cardiology OP 
referrals  by  the  referring  doctor  is  exactly  offset  by  the 
generation of new cardiology OP referrals from the CPC. 
However, 95% GP referrals (84% all referrals) to the CPC 
were seen within 1 week. Additional work was captured that 
would have been referred to the CPC of another hospital. 
 
Isolated  T3  toxicosis  complicating  metastatic  thyroid 
follicular thyroid cancer: a trap for the unwary during long-
term thyroxine suppression therapy.
JR  Lindsay1,  DP  Rooney2,  FM  Pollock1,  A  Lewis,  SJ 
Hunter1.
1Regional  Centre  for  Endocrinology  and  Diabetes,  Royal 
Victoria Hospital, Belfast, BT12 6BA, 2Antrim Area Hospital, 
Antrim, BT41 2RL
We present a case of a 63 year old man who developed T3-
toxicosis  13  years  following  thyroidectomy  and  ablative 
radioiodine  therapy  for  follicular  thyroid  cancer  (FTC). 
Although asymptomatic (free T4 18.4 pmol/l, TSH <0.01 
mU/l) while taking levothyroxine (T4) 200 µg/d during long-
term suppressive thyroxine therapy he later presented with 
uncontrolled atrial fibrillation and congestive cardiac failure.   
Thyrotoxicosis  due  to  excessive  levothyroxine  intake  was 
considered however free T4 levels were similar to previous 
measurements  (14.7  pmol/l).   The  possibility  of  isolated 
T3-toxicosis was suspected and confirmed (free T3 levels 
varying between 10.5-23.8 nmol/l). Iodine-avid pulmonary 
and hepatic metastases were visualized on I123 scanning, in the 
absence of neck uptake, and thyroxine therapy was withdrawn 
prior to further treatment of 3700 MBq I131. 
Comment: Thyrotoxicosis caused by thyroid cancer occurs 
rarely  and  is  usually  due  to  follicular  neoplasia,  often  in 
association with pulmonary and/or bony metastatic disease. 
As in this case, the biochemical profile is frequently that of 
isolated T3-toxicosis. While treatment and survival of cases 
with thyrotoxicosis appear similar to euthyroid cases with 
FTC, development of hyperthyroidism implies a large tumour 
bulk due to reduced iodine concentrating efficiency. We await 
clinical and biochemical responses to I131 in this case however 
his prognosis remains guarded.
ST elevation in lead aVR during exercise testing should not 
be ignored.
J Neill1,2, A Morton1, J Shannon1,2, A Muir1,2, M Harbinson1,2, 
AAJ Adgey1,2.
1Regional  Medical  Cardiology  Centre,  Royal  Victoria 
Hospital,  Belfast,  United  Kingdom.  2 Queens  University 
Belfast
The significance of ST elevation (STE) in lead aVR during 
exercise is controversial.  We aimed to assess the diagnostic 
value of STE in aVR during exercise prior to Tc99-sestamibi 
scanning  and  its  predictive  value  in  identifying  ischemic 
territory and angiographic findings.
Consecutive patients for Tc99-sestamibi perfusion imaging 
between April  and Aug  2004  were  enrolled.   Their  peak 
exercise ECGs were coded by 2 blinded investigators.  STE 
≥0.05mV  in  lead  aVR  was  significant.    Gated  perfusion 
imaging and angiographic findings were assessed.  
STE in lead aVR occurred in 25% (138/557) of patients.   
More patients with STE in aVR had reversible defects on 
imaging compared with those that had no STE in aVR (41% 
56/138 vs 27% 114/419, p = 0.003).  Defects indicating a left 
anterior descending artery (LAD) culprit lesion were more 
common in the STE aVR group (20% 27/138 vs 9% 39/419, 
www.ums.ac.uk
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